MarketingMedicalPolicy,Access,Value, andEvidenceConsultingData,Technology,and Media
murmuration of birds
Previous
Next

thought leadership

Cell and gene therapy market access in the Asia-Pacific region

1/22/2024

Watch the webinar.

This webinar delves into the cell and gene therapy (CGT) landscape in the Asia-Pacific (APAC) region. It examines market access dynamics for both global and local CGT products and uncovers the crucial factors that manufacturers need to consider to optimize CGT access in APAC.

Watch the on-demand recording.

Fill out the form below

 

 

Exploring new horizons: Cell and gene therapy access in APAC

In the APAC region, evaluating CGTs for reimbursement is still a relatively new concept in the context of market access.

Payers are developing their perspectives on the value of innovative therapies and determining effective ways to assess them using existing health technology assessment (HTA) methods or modifying them as necessary. Additionally, innovative financing and payment models are in their early stages of exploration.

As global CGT leaders seek entry into these markets, the competitive local CGT landscape adds an extra layer of complexity. To ensure timely access to CGTs in the evolving APAC payer landscape, a profound understanding of the market access dynamics for these therapies and associated technologies is essential.

 

Learning objectives
  • Understand the evolving APAC cell and gene therapy regulatory and reimbursement landscape
  • Gain insights into the CGT capabilities of local biotechs in APAC and where their products are today
  • Discover how global learnings for overcoming hurdles to optimal CGTs access can be adapted for the APAC region
  • Delve into critical considerations for building the necessary ecosystems to successfully deploy CGTs in the APAC region

 

Speakers

 


Jose Manuel Garnica, independent thoughtleader 
An independent thought-leader within Market Access, Pricing, and Health Economics, Jose Manuel has expertise in early asset development and launch, strategic evidence generation planning, and achieving access for CGTs. Jose Manuel’s roles in industry have led him to directly work in several key markets worldwide including the US, Canada, Europe, the Asia-Pacific region (APAC), the Middle East and Latin America. He has held senior positions in Bristol Myers Squibb, Pfizer, Roche, and Amgen, and most recently spearheaded APAC market access for Kite, a leading global biotech in the cell therapy space. 

Jose Manuel holds a PhD from Imperial College London and an MBA from London Business School. He is currently also a Guest Lecturer at the University
of Southern California in Los Angeles.

Jeff Weisel, Senior Strategic Advisor
Jeff has 25+ years’ experience in APAC and emerging markets, working with leading life sciences organizations on issues of strategic and business innovation, and access to healthcare. His experience has encompassed executive positions in the pharmaceutical industry and leadership of Big-4 consulting practices helping deliver the success of top global brands and he also played a key role in industry policy engagement with PhRMA.
Sudha Sundaram, Associate Director
Sudha has 7 years’ experience within market access consulting, life sciences academic research, and business development in the APAC region. Her work has involved market opportunity assessment, pricing and reimbursement potential evaluation, real-world evidence capabilities mapping, and new technology scoping projects. Her work has spanned multiple therapeutic areas including a focus on innovative therapies such as CAR-Ts.
Ye Huang, Senior Consultant
Ye has several years’ consultancy experience in health technology assessment and market access across Europe, Asia, the Middle East, and Latin America. She has worked on multiple projects on market access, pricing and reimbursement strategy, market risks and opportunity assessments, evidence generation planning, and cost-effectiveness and budget impact modeling.
Vesshnu Sutharsan, Consultant
Vesshnu has a number of years’ experience in healthcare consulting, including in primary market research, payer and market landscape assessment, early pipeline planning, go-to-market strategy formulation, HTA/HEOR, and review of cross-border innovative contracting and financing strategies for ultra high-cost therapies. He has also been involved in numerous access projects in oncology and immunology at Avalere Health.

 

How we use cookies

Cookies are files saved on your phone, tablet or computer when you visit a website.

We use cookies to store information about how you use the Fishawack Health website, such as the pages you visit.

For more information, check the cookie statement

32E8261E-A569-4B66-ACC6-3CB772DDEDEE

Cookie settings

We use 4 types of cookies. You can choose which cookies you're happy for us to use.

Cookies that measure website use.

We use Google Analytics to measure how you use the website so we can improve it based on user needs. We do not allow Google to use or share the data about how you use this site.

  • how you got to the site
  • the pages you visit on fishawack.com, and how long you spend on each page
  • what you click on while you're visiting the site

Cookies that help with our communications and marketing

These cookies may be set by third party websites and do things like measure how you view Vimeo videos that are on Fishawack.com.

Cookies that remember your settings

These cookies do things like remember your preferences and the choices you make, to personalize your experience of using the site.

Strictly necessary cookies

These essential cookies do things like remember your progress through a form (eg. Registering for new content alerts).

These cookies always need to be on.